From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Mericitabine structure.png
Clinical data
Trade names Mericitabine
Legal status
Legal status
CAS Number
PubChem CID
Chemical and physical data
Formula C18H26FN3O6
Molar mass 399.419
3D model (JSmol)

Mericitabine (RG-7128) is an antiviral drug, a deoxycytidine analog (a type of nucleoside analog). It was developed as a treatment for hepatitis C, acting as a NS5B RNA polymerase inhibitor, but while it showed a good safety profile in clinical trials, it was not sufficiently effective to be used as a stand alone agent. However mericitabine has been shown to boost the efficacy of other antiviral drugs when used alongside them, and as most modern treatment regimens for hepatitis C use a combination therapy of several antiviral drugs, clinical trials have continued to see if it can form a part of a clinically useful drug treatment program.[1][2]

See also[edit]


  1. ^ Gentile, I; Coppola, N; Buonomo, A. R.; Zappulo, E; Borgia, G (2014). "Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus". Expert Opin Investig Drugs. 23 (9): 1211–23. doi:10.1517/13543784.2014.921680. PMID 24848437. 
  2. ^ Wedemeyer, H; Forns, X; Hézode, C; Lee, S. S.; Scalori, A; Voulgari, A; Le Pogam, S; Nájera, I; Thommes, J. A. (2016). "Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies". PLoS One. 11 (1): e0145409. Bibcode:2016PLoSO..1145409W. doi:10.1371/journal.pone.0145409. PMC 4713467Freely accessible. PMID 26752189.